A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression
Por:
Almaghrabi, R, Alyahyawi, Y, Keane, P, Mian, SA, Habel, K, Atkinson, A, Ward, C, Bayley, R, Sargas, C, Menendez, P, Murphy, GJ, Sobahy, T, Baghdadi, MA, Flemban, AF, Kabrah, SM, Torres-Ruiz, R, Papapetrou, EP, Akerman, I, Raghavan, M, Barragan, E, Bonnet, D, Bonifer, C and Garcia, P
Publicada:
1 jul 2025
Ahead of Print:
1 jul 2025
Resumen:
Myelodysplastic syndrome disease (MDS) is caused by the successive acquisition of mutations and thus displays a variable risk for progression to AML. Mutations in CEBPA are commonly associated with a high risk of disease progression, but whether they are causative for AML development is unclear. To analyse the molecular basis of disease progression we generated MDS patient-derived induced pluripotent stem cells from a low risk male patient harbouring RUNX1/SRSF2 mutations. This experimental model faithfully recapitulates the patient disease phenotypes upon hematopoietic differentiation. Introduction of a frameshift mutation affecting the C/EBP alpha bZIP domain in cells from low-risk stages mimicks disease progression by reducing clonogenicity of myeloid cells, blocking granulopoiesis and increasing erythroid progenitor self-renewal capacity. The acquisition of this mutation reshapes the chromatin landscape at distal cis-regulatory regions and promotes changes in cellular composition as observed by single cell RNAseq. Mutant C/EBP alpha is therefore causative for MDS disease progression. Our work identifies mutant CEBPA as causative for MDS disease progression, providing a new isogenic MDS experimental model for drug screening to improve diagnostic and therapeutic strategies.
Filiaciones:
Almaghrabi, R:
Univ Birmingham, Coll Med & Hlth, Dept Canc & Genom Sci, Birmingham B15 2TT, England
Albaha Univ, Fac Appl Med Sci, Dept Lab Med Haematol, Al Bahah, Saudi Arabia
Alyahyawi, Y:
Univ Birmingham, Coll Med & Hlth, Dept Canc & Genom Sci, Birmingham B15 2TT, England
Jazan Univ, Coll Nursing & Hlth Sci, Dept Med Lab Technol, Jazan, Saudi Arabia
Keane, P:
Univ Birmingham, Sch Biosci, Coll Life & Environm Sci, Birmingham B15 2TT, England
Mian, SA:
Francis Crick Inst, Haematopoiet Stem Cell Lab, London NW1 1AT, England
Habel, K:
Francis Crick Inst, Haematopoiet Stem Cell Lab, London NW1 1AT, England
Atkinson, A:
Univ Birmingham, Coll Med & Hlth, Dept Canc & Genom Sci, Birmingham B15 2TT, England
Ward, C:
Univ Birmingham, Coll Med & Hlth, Dept Canc & Genom Sci, Birmingham B15 2TT, England
Bayley, R:
Univ Birmingham, Coll Med & Hlth, Dept Canc & Genom Sci, Birmingham B15 2TT, England
Sargas, C:
Hosp Univ & Politecn La Fe, Clin Anal Serv, Mol Biol Unit, Valencia 46026, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid 2029, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
Univ Barcelona, Sch Med, Dept Biomed, Barcelona, Spain
Hosp St Joan de Deu, Inst Recerca, Pediat Canc Ctr Barcelona SJD PCCB, Barcelona, Spain
Murphy, GJ:
Boston Univ, Sch Med, Dept Med, Sect Hematol & Oncol, Boston, MA 02118 USA
Boston Univ, Ctr Regenerat Med CReM, Boston, MA 02215 USA
Boston Med Ctr, Boston, MA 02118 USA
Sobahy, T:
King Faisal Specialist Hosp & Res Ctr Jeddah, Res Ctr, Jeddah, Saudi Arabia
Baghdadi, MA:
King Faisal Specialist Hosp & Res Ctr Jeddah, Res Ctr, Jeddah, Saudi Arabia
Flemban, AF:
Umm Al Qura Univ, Fac Med, Pathol Dept, Mecca, Saudi Arabia
Kabrah, SM:
Umm Al Qura Univ, Fac Appl Med Sci, Dept Clin Lab Sci, Mecca, Saudi Arabia
Torres-Ruiz, R:
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Ctr Nacl Invest Oncol CNIO, Human Canc Genet Program, Mol Cytogenet & Genome Editing Unit, Madrid, Spain
Ctr Invest Energet Medioambientales & Tecnol CIEMA, Div Hematopoiet Innovat Therapies, Biomed Innovat Unit, Madrid, Spain
Inst Invest Sanitaria Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain
Papapetrou, EP:
Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY USA
Icahn Sch Med Mt Sinai, Ctr Adv Blood Canc Therapies, New York, NY USA
Akerman, I:
Univ Birmingham, Coll Med & Hlth, Dept Metab & Syst Sci, Birmingham, England
Raghavan, M:
Univ Birmingham, Coll Med & Hlth, Dept Canc & Genom Sci, Birmingham B15 2TT, England
Barragan, E:
Hosp Univ & Politecn La Fe, Clin Anal Serv, Mol Biol Unit, Valencia 46026, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid 2029, Spain
Bonnet, D:
Francis Crick Inst, Haematopoiet Stem Cell Lab, London NW1 1AT, England
Bonifer, C:
Univ Birmingham, Coll Med & Hlth, Dept Canc & Genom Sci, Birmingham B15 2TT, England
Royal Childrens Hosp, Ctr Stem Cell Med, Murdoch Childrens Res Inst, Novo Nordisk Fdn, 50 Flemington Rd, Parkville, Vic 3052, Australia
Garcia, P:
Univ Birmingham, Coll Med & Hlth, Dept Canc & Genom Sci, Birmingham B15 2TT, England
Green Submitted, gold
|